These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39160415)

  • 1. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.
    Cedillo S; González-Domínguez A; Ivanova-Markova Y; López López R; López-Tarruella Cobo S; Peña Pedrosa JA
    Pharmacoecon Open; 2024 Nov; 8(6):887-896. PubMed ID: 39160415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
    Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
    Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
    Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.
    Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB
    JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
    Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
    Cedillo S; Garí C; Aceituno S; Manso L; Cercos Lleti AC; Ventayol Bosch P; Casado A; Perez Fidalgo A
    Int J Gynecol Cancer; 2024 Feb; 34(2):277-284. PubMed ID: 38054270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
    Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
    Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
    Sra MS; Sasi A; Batra A; Bakhshi S; Ganguly S
    JCO Glob Oncol; 2024 Jul; 10():e2300433. PubMed ID: 39024528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
    Shu Y; Liu Y; He X; Ding Y; Zhang Q
    Front Pharmacol; 2022; 13():818579. PubMed ID: 36034834
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.
    Kwong A; Leung R; Chan TC; Khandelwal A; Mishra K; Huang M
    Oncol Ther; 2024 Sep; 12(3):525-547. PubMed ID: 39037537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
    Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
    J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
    Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
    Ioannou SS; Marcou Y; Kakouri E; Talias MA
    Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
    Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
    Nie J; Wu H; Sun L; Ding Y; Luan Y; Wu J
    Front Pharmacol; 2022; 13():987337. PubMed ID: 36686677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.